Introduction
The term primary central nervous system (CNS) lymphoma (PCNSL) currently refers to lymphomas arising exclusively in the CNS, that is, the brain parenchyma, spinal cord, eyes, cranial nerves and/or meninges. The incidence of PCNSL in immunocompetent patients has significantly increased during the last decades, thus, necessitating studies addressing the biology, pathogenesis and therapy in order to improve the still poor prognosis as compared with lymphoma at other sites. Approximately 95% of PCNSL are mature non-Hodgkin B-cell lymphomas, morphologically indistinguishable from systemic diffuse large B-cell lymphoma (DLBCL) of other organs.
However, despite sharing some common features with DLBCL, PCNSL is distinct in others. These observations as well as the clinical course and worse outcome of patients with PCNSL have fostered intense efforts in basic and clinical research during recent years to elucidate the biology of PCNSL, to improve therapeutic results and to identify new effective strategies.
This report highlights recent developments in the field of PCNSL with an impact on the molecular pathogenesis, diagnosis, differential diagnosis and therapeutic studies.
Clinical presentation of PCNSL and diagnostic procedures
PCNSL typically presents as an intra-cranial mass lesion, usually with a combination of generalized symptoms such as headache, confusion and lethargy, as well as lateralizing symptoms such as hemiparesis. 1 These symptoms usually lead to neuroimaging, and either MRI (the preferred test) or CT scans demonstrate briskly enhancing lesions that are often peri-ventricular and lack central necrosis so the enhancement is diffuse; surrounding edema is variable. The tumor is single in 60-70% of patients and multiple in the remainder. 2 Almost all immunodeficient patients have multiple lesions at diagnosis. In addition to brain involvement, the eye is involved in about 20% of patients, only half of whom have any visual complaints; visual symptoms are typically floaters or blurred vision. 3 Concurrent leptomeningeal involvement is seen in about 18% of patients, based on cerebrospinal fluid (CSF) analysis, 4 but rarely do these patients have any symptoms suggestive of subarachnoid tumor infiltration. Even less common than parenchymal brain PCNSL is isolated ocular lymphoma 5 or primary leptomeningeal lymphoma, 6 both of which are considered variants of PCNSL. Diagnosis is usually established by brain biopsy, but avoidance of glucocorticoids prior to surgery is highly important as steroids may cause rapid, but temporary, tumor lysis making neuropathological diagnosis difficult or even impossible. Surgical resection has not been found to contribute to disease control 7 and, therefore, resection is not recommended. This is part of the challenge in understanding the biology of PCNSL because tumor specimens are rare and small.
Clinical features are important prognostic factors in patients with PCNSL. Virtually all studies confirm the importance of age and performance status, which have been integrated in two scoring systems for newly diagnosed PCNSL patients. 8, 9 Histopathology and differential diagnosis of primary DLBCL of the CNS Phenotypically, nearly all PCNSL express pan-B-cell markers such as CD20, CD19, CD22 and CD79a. The majority of PCNSL expresses BCL-6 (60-80%), a marker of germinal-center (GC) B cells, and IRF4/MUM1 (90%), a marker of late GC B cells and plasma cells, with approximately 10% being CD10 þ . The extremely high proliferative activity, with often more than 90% of the tumor cells expressing the Ki67 antigen, is a striking feature. 10 Involvement of the CNS can occur in virtually all generalized nodal and extra-nodal lymphoma entities, but with variable incidence rates. When lymphoma presents in the brain, secondary involvement of a potentially generalized nonHodgkin lymphoma needs to be excluded. As CNS involvement is rare in indolent lymphomas such as follicular lymphoma or mantle cell lymphoma (1 of 1307 and 1 of 470 cases with extranodal involvement in the German Low Grade Lymphoma Study Group, respectively), 11 aggressive non-Hodgkin lymphomas, which frequently show CNS involvement, have to be considered. 12 The most important differential diagnosis includes Burkitt lymphoma and lymphoblastic lymphoma, which show CNS involvement in 5-10% of all cases. 13 In addition, HIVassociated PCNSL has to be considered in the differential diagnosis of CNS lymphomas, although it has become much rarer with the introduction of highly active antiviral therapy. 14 Recently, a possible association between the development of CNS lymphoma and natalizumab, a monoclonal antibody approved for the therapy of active multiple sclerosis, which impairs immune surveillance, has been suggested. 15 Generally, an association of multiple sclerosis (MS) and PCNSL appears highly unlikely. In the reported MS patient treated with natalizumab who developed PCNSL, PCNSL may be either unrelated to MS disease activity or natalizumab therapy, or one may hypothesize that natalizumab may have impaired immune responses, thereby allowing lymphoma development in the CNS. The inclusion of Epstein-Barr virus encoded RNA in situ hybridization into the diagnostic standard for CNS lymphoma will also help to identify other immunodeficiency-associated lymphoproliferative disorders, which might manifest as isolated CNS tumors such as lymphomatoid granulomatosis. 16 A suggested staining panel for the differential diagnosis of aggressive lymphomas in the CNS is outlined in Table 1 . Primary lymphoma of the dura seems to be rare, primarily resembling marginal zone lymphoma and, thus, is easily distinguishable from DLBCL of the CNS. 17 Primary T-cell lymphoma confined to the CNS is extremely rare and has been reported only incidentally. [18] [19] [20] In general, all neuroepithelial tumors and metastatic lesions of various origins need to be considered in the differential diagnosis of PCNSL. Here, we concentrate on the distinction from histiocytic lesions, which make up less than 0.2% of all mass lesions encountered in the nervous system and its coverings. Langerhans cell histiocytosis (LCH) and various types of (non-neoplastic) xanthogranulomas represent the major groups, each of which constitutes 40-45% of histiocytic lesions leading to neurological symptoms. The wide variety of other histiocytic lesions is extremely rare, but may occur and have to be considered in the differential diagnosis.
LCH with involvement of the nervous system most commonly arises from osseous lesions including the skull and spine, with secondary involvement of the brain or spinal cord. However, LCH may occur primarily in the brain, such as in the hypothalamus, optic chiasm, choroid plexus and cerebral hemispheres. The neuropathological diagnosis of LCH is usually straightforward based on the typical histological pattern and immunoreactivity for the CD1a, CD207 (langerin) and S-100 protein. However, CD1a expression can be lost in granulomas, which persist for longer time within the CNS. 21 Additional problems may arise on rare occasions of malignant LCH, a disease with multi-organ involvement and a median survival of 2 years, and the neurodegenerative (inflammatory) type of LCH, which is a diffuse, inflammatory, presumably cytokine-mediated process involving large areas of the brain with CD8 þ T lymphocytes, loss of Purkinje cells, axons and myelin, and absence of CD1a þ Langerhans cells. 21 Xanthogranulomas (cholesterol granulomas) are reactive mass lesions consisting of cholesterol clefts, macrophages, hemosiderin deposits, fibrosis and chronic inflammation. The most common location of LCH granulomas is the sellar region (to be differentiated from craniopharyngioma), followed by the petrous apex, the choroid plexus and the orbit.
In principle, each type of histiocytic tumor or pseudo-tumor may occur in intra-cranial or intra-spinal locations. Examples include Erdheim-Chester disease (about 200 neurological cases on record), Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy, about 100 cases), juvenile xanthogranuloma (about 30 cases), histiocytic sarcoma (six cases), histiocytic chloroma (extramedullary myeloid sarcoma), follicular dendritic cell sarcoma and xanthoma (tumor-like accumulation of macrophages in the dura). Most of these In addition to tumors, non-tumorous lesions, in particular inflammatory conditions have to be considered. Neuropathological classification and their differentiation from PCNSL relies on the composition of the inflammatory infiltrates and the type of tissue injury associated with the inflammatory process. 22 Multiple sclerosis must be excluded particularly in younger patients with atypical manifestation. While demyelination is generally absent in PCNSL, it may not be prominent in tiny MS biopsies. If B cells, which may be enlarged owing to their activation, dominate the infiltrate, accurate diagnosis may require PCR analysis of B-cell receptor rearrangement to exclude monoclonality. A special problem arises in rare occasions, when lymphoma is associated with MS-like primary demyelination (lymphoma with sentinel lesions 22 ) and the biopsy is performed after the initiation of high-dose steroid treatment. It is currently not clear whether such demyelination is a genuine feature of the lymphoma or reflects an association of lymphoma with MS, which can be induced as a consequence of immunosuppressive treatment.
CNS vasculitis is another diagnostic possibility that has to be considered. CNS vasculitis is a heterogeneous disorder; both primary and secondary forms of vasculitis, the latter including infections, systemic vasculitides, connective tissue diseases and various rare disorders, have to be distinguished. The spectrum and differential diagnosis of cerebral vasculitis has been discussed in detail by Haji-Ali and Calabrese. 23 In cases, which show characteristic morphological features such as inflammatory infiltrates within and around cerebral blood vessels, necrosis of blood vessel walls and thrombotic occlusion associated with ischemic changes of the corresponding brain parenchyma, in the absence of mass lesion(s), distinction from PCNSL is easily performed. However, biopsy samples may not show (all of) these morphological characteristics, particularly, if samples are small, as vasculitic changes may be regionally confined. In these cases, differentiation from PCNSL may be difficult, as the tumor cells of PCNSL have a tendency to reside within blood vessel walls and to split the blood vessel walls. In cases with enlarged T-or B-lymphocytes, PCR analysis of B-and T-cell receptors, respectively, may be required to exclude monoclonality.
Biology of PCNSL
In order to address the molecular pathogenesis of PCNSL, during the last decade research strongly focused on mutations in candidate oncogene and tumor-suppressor gene loci, which may lead to malignant transformation of B cells. These include translocations of the IG loci (38%) 24 and the BCL6 gene (23%); 24 point mutations in CD95 (20%), PAX5 (60%), TTF (70%), PIM1 (50%), CMYC (60%), 25 and PRDM1 (19%); 26 and gains and losses of genetic material ( Figure 1 ). 27 IG translocations are recurrent in PCNSL, with frequencies similar to systemic DLBCL. Regarding IG translocations, the translocation partners identified in nodal DLBCL were yet not involved in PCNSL. 24 Interestingly, instead of alterations of a single gene, deregulation of specific pathways is more relevant for lymphomagenesis. One important pathway is nuclear factor-kB (NF-kB), which is generally active in PCNSL, as evidenced by increased expression of NF-kB-regulating genes, genes of the NF-kB complex, NF-kB target genes 28 and the nuclear location of the p50 protein in the tumor cells. 29 Amplification of the MALT1 gene (37%) and activating mutations of the CARD11 gene (16%) in a fraction of PCNSL underlie these alterations. 24, 29 In contrast to nodal DLBCL, 30, 31 inactivating mutations of TNFAIP3 do not have a major role in activating the NF-kB pathway in PCNSL (10%, 1 of 10 cases). 29 Gene expression profiling of PCNSL has, so far, been restricted to four studies owing to limitation of biopsy size. [32] [33] [34] [35] However, the results differed between the various studies, which can be explained, at least in part, by the differences in the platform used and the algorithm applied. One study claimed to have identified a characteristic CNS signature, 35 but this could not be confirmed by others. High expression of activated STAT6 was associated with a shorter survival in patients treated with high-dose intravenous methotrexate (MTX) monochemotherapy. 34 Combined gene expression profiling and array comparative genomic hybridization pointed to the concept of immunoprivileged-site DLBCL, that is, of brain and testis, to differentiate from DLBCL Figure 1 The pathogenesis of PCNSL. There is evidence for several pathways to be critically involved in the pathogenesis of PCNSL. These target a variety of genes, which become deregulated, ultimately leading to uncontrolled proliferation, impairment of apoptosis or B-cell differentiation, or may interfere with the sensitivity of the tumor cells to immune responses in the CNS. ASHM, aberrant somatic hypermutation; CSR, class switch recombination; SHM, somatic hypermutation. 32 Genome-wide single-nucleotide polymorphism chip analysis demonstrated loss of 6p21 including the human leukocyte antigen region (37%), which may indicate an escape mechanism of the tumor cells from the immune response. 27, 32 In addition, gains affected chromosome 12 (26%), and 18q21.33-q23 (43%), whereas losses involved 6q21 (52%), 8q12.1-q12.2 (32%) and 10q23.21 (21%). 27, 32 In both of these studies, data were correlated with gene expression profiling. A deletion of 6p21 was associated with a reduced expression of major histocompatibility complex mRNA. 32 A loss of 10q23 was associated with the absence of Fas mRNA, whereas gains of chromosome 12 were associated with an upregulation of STAT6 and CD27 mRNA, 27 which may also contribute to the enhanced proliferation and impaired apoptosis of PCNSL tumor cells. 10 In the field of epigenetics, initial analyses revealed silencing of individual genes including RFC (30%), DAPK (84%), CDKN2A (75%) and MGMT (52%) 27, [36] [37] [38] owing to hypermethylation of their corresponding CpG islands. In stem cells many genes are switched off by polycomb-repressing complexes. Recent studies demonstrated that genes switched off by promoter methylation in PCNSL belong to these polycombrepressing complex-regulated genes in addition to genes involved in tumorigenesis and lymphocyte motility, 39 which may also facilitate tumor cell spread within the CNS. While stem cells establish such a status by remodeling their chromatin structure following expression of proteins of the polycomb group, the tumor cells in PCNSL silenced similar genes by methylation. One may speculate that this methylation process may contribute to the generation of premalignant precursor cells. 40 Tumor cells of PCNSL are derived from GC B cells and are characterized by a high load of somatic mutations, with a mean mutation frequency 2-to 5-fold higher than normal peripheral B cells. 41 Moreover, they frequently show ongoing somatic hypermutation, a hallmark of GC B cells. 41, 42 A peculiar finding is a very biased usage of VH gene segments, as IGHV4-34 was rearranged in 50-80% of PCNSL. 41, 42 This might indicate that triggering through particular antigen(s) has a role in early PCNSL development. Interestingly, the V4-34 gene segments often encode autoreactive antibodies, and V4-34-expressing B cells appear to be usually excluded from participating in GC reactions and entering the post-GC memory or plasma cell pool. 43 There is evidence from single reports on an original PCNSL and its relapse that both tumors shared a common ancestor, presumably a premalignant precursor cell. 44, 45 IGH gene analysis identified the same V, D and J gene segments, and almost identical CDR3 sequences, in cells of the primary and recurrent tumor, respectively. While they shared several mutations in their V gene segments, each tumor-related sequence was characterized by unique mutations. 45 Interestingly, tumor sequence-related clones could be identified in the blood and/or bone marrow from some patients with PCNSL, who had no evidence of systemic lymphoma. 46, 47 Recent studies of IgM/IgD memory B cells revealed the presence of hundreds to thousands of related clone members for IgM/IgD memory B cells in the peripheral blood. 48 Therefore, the presence of several tumor-related clones, one of which may have entered the CNS either as a premalignant or malignant cell, may not be specific for lymphomagenesis, but rather reflect normal behavior of memory B-cell development.
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Molecular pathogenesis and therapeutic options in PCNSL
Owing to intense efforts during recent years, multiple mechanisms, which may have a role in the malignant transformation of the B cells in PCNSL, have been dissected. However, there is no evidence for a transforming event unique to the tumor cells of PCNSL. Despite these advances, the precise pathogenesis of PCNSL is still unknown, in particular, the selective and exclusive manifestation in the CNS. In this regard, several hypotheses, which are not mutually exclusive, may be discussed.
Malignant transformation may occur within or outside the CNS. Outside the CNS, cells engaged in a GC reaction may acquire transforming events, for example, through aberrant somatic hypermutation or misguided class switching causing chromosomal translocations. With respect to a possible malignant transformation in the CNS, B cells may encounter their antigen in the CNS, and, during an aberrant GC reaction within the brain, may receive a transforming hit, with their proliferation being stimulated while apoptosis is inhibited.
The exclusive manifestation of PCNSL in the CNS and the usual confinement of relapses to the CNS may also be caused by various mechanisms. First, B cells having transformed in the periphery, may spread ubiquitously throughout the organism and may have been eliminated outside the CNS by a specific antitumor immune response, whereas they escape from the immune response in the CNS, where immune responses are generally downregulated and more tightly controlled owing to the immunoprivileged status of the CNS, resulting in a growth advantage of the tumor cells within the brain.
Second, upon transformation, the malignant B cells may have acquired a high affinity and tropism for the CNS, stimulating their specific homing to the CNS. However, so far, a specific expression pattern of the cell adhesion molecules and the chemokines of the tumor cells could not be substantiated. 49, 50 Nevertheless, the tumor cells may show characteristic features, which enable or enhance their specific interaction with CNS cell populations, and which also foster their survival in the CNS. In this regard, the observation of a confinement of these lymphomas to immunoprivileged organs, that is, the CNS and testis, may be important. 51 Third, non-or pre-malignant B cells enter the CNS either accidentally when the permeability of the blood-brain barrier (BBB) is increased or during a (pathogen)-induced inflammation. As it is well-known from animal models of chronic CNS infections that B cells may persist within the brain, 52 mostly in a perivascular localization, one may envisage a scenario for PCNSL that after termination of an intracerebral immune response, low numbers of B cells may persist in the CNS and receive (a) transforming hit(s) later, leading to lymphoma development even after extended time periods.
While at present it cannot be decided which of these hypotheses are in fact relevant for the pathogenesis of PCNSL, we would favor the first and second hypotheses as they are supported by data (pattern of somatic mutations of the tumor cells suggest an antigen-driven process and antigen selection; 41 relapse of PCNSL confined to the immunoprivileged organs CNS and/or testis; 51 gene expression profiling of PCNSL samples indicates interaction with resident cell populations of the CNS 33 ). Nevertheless, all of these hypotheses need to be tested in order to answer this intriguing question of PCNSL pathogenesis, which is not only of basic neuroimmunological interest, but also of relevance with respect to the development of specific therapeutic regimens.
Treatment of PCNSL
Background
PCNSL is sensitive to chemotherapy and radiotherapy so that durable complete remissions (CRs) have become possible.
However, the outcome is still unsatisfactory when compared with other lymphoma entities. Current therapeutic knowledge in PCNSL is mainly based on retrospective analyses, case series and single-arm phase-II studies; [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] so far, only one randomized phase-II trial 72 and two phase-III trials 73, 74 have been reported. Thus, the level of evidence for therapeutic choices in PCNSL is still low. There are only a few drugs with acceptable CNS bioavailability that can be safely incorporated in new regimens for this malignancy, whereas drugs used for the treatment of systemic lymphoma have mostly proven ineffective in PCNSL.
Role of surgery
Open surgery for tumor resection is not indicated as the procedure potentially induces neurological deficits, with neither evidence for therapeutic benefit nor evidence for improvement of prognosis. 7 Stereotactic guided biopsy is the method of choice to establish the definite diagnosis of PCNSL and intraoperatively performed neuropathological analysis will detect the lymphoid blasts. Prior to stereotactic biopsy, administration of steroids should be avoided as this may interfere with or even prevent the histopathological diagnosis of PCNSL. Biopsy after resolution or shrinkage of cerebral lesions owing to steroids is not promising and should be avoided; however, in progressive lesions, despite steroids it may be diagnostic. 75 Steroids before biopsy may be allowed in the setting of life-threatening increased intracranial pressure.
Role of radiotherapy
Whole-brain radiotherapy (WBRT) had been the standardof-care as primary therapy for PCNSL into the early 1990s, producing CR rates of 80-90%. However, even with doses up to 60 Gy, long-term disease control was poor, with relapse occurring in almost all patients, resulting in a median overall survival (OS) of 12-16 months and a 5-year OS of 10-29%. 74, 76, 77 Subsequently, better response rates and improved survival were reported in clinical trials using high-dose (HD)-MTXbased chemotherapy followed by WBRT. CR rates ranged between 69 and 87% using combined chemo-radiotherapy, with a median progression-free survival (PFS) of 24-40 months. 54, 59, 60, 62, 66, 69, 70 This resulted in a widespread use of combined modality treatment in the primary management of PCNSL. Unfortunately, with longer follow-up, severe neurological impairment, including dementia and death, developed after combined treatment particularly in older patients. 78, 79 This led to the investigation of radiotherapy dose reduction and radiotherapy withdrawal in patients with a CR after chemotherapy alone; however, the data are conflicting. In a phase-II study involving 30 patients and a short follow-up, satisfactory disease control without late neurotoxicity was achieved when the WBRT dose was reduced from 45 to 23.4 Gy in CR patients after chemotherapy. 71 By contrast, WBRT dose reduction from 45 to 30.6 Gy in younger patients in CR after chemotherapy had significantly increased the risk of relapse and decreased OS in an older, small, phase-II study. 56 When WBRT was completely withdrawn in patients with CR after HD-MTX-based chemotherapy, PFS was 13-17 months after single-agent HD-MTX 55, 63, 64 and 21 months with combination chemotherapy. 68 Furthermore, a retrospective analysis did not find a survival benefit for WBRT when added to primary chemotherapy. 61 However, these studies suffer from imbalance of prognostic factors and selection bias, different treatment variables, short follow-up, differences in study methodology and lack of adequate neuropsychological assessment.
In the only randomized phase-III trial of 551 patients with newly diagnosed PCNSL (G-PCNSL-SG1), there were no significant differences in OS when WBRT (45 Gy with fractions of 1.5 Gy) was omitted from primary therapy (after HD-MTXbased chemotherapy): 73 OS in the per-protocol population was 32.4 months with WBRT and 37.1 months without WBRT (P ¼ 0.7). However, a benefit for PFS was found (18.3 versus 11.9 months, P ¼ 0.13), which proved significant in subgroup analyses, suggesting an important role of WBRT for control of disease. The upfront randomization, the high number of protocol variations and a lack of detailed neuropsychological analyses are the limitations of this trial and illustrate the difficulties in conducting randomized (phase-III) trials in patients with PCNSL. Nevertheless, with a median age of 63 years, with 24% of the patients being older than 70 years and 15% of patients presenting with Karnovsky performance status o40%, this trial may well reflect the community spectrum of PCNSL as compared with patients who have been selected by age. The results of this trial may indicate that WBRT can be omitted from primary treatment of PCNSL.
When WBRT was used as salvage therapy, a response rate of 60-79% and an OS of 10.9-16 months was reported. 80, 81 Response rates to WBRT and survival were similar between refractory and recurrent patients. 80 
Chemotherapy
Chemotherapy has a central role in the management of patients with PCNSL. However, efficacy is limited by several factors, including the biology and the microenvironment of this malignancy that is protected by the BBB. Thus, drugs for patients with PCNSL need to cross the BBB and can be divided into three groups: (1) Drugs with poor penetration of the BBB having little activity in PCNSL (anthracyclines, vinca-alkaloids, cyclophosphamide); (2) Drugs showing a moderate capability to cross the BBB that can be safely administered at high doses to obtain therapeutic concentrations in the CNS (MTX and cytarabine, Ara-C); and (3) Drugs that can cross the BBB and reach therapeutic concentrations in the tumor even when administered at conventional doses (glucocorticoids and temozolomide). The CHOP (cyclophosphamide, vincristine, doxorubicin) regimen, the combination most commonly used to treat aggressive lymphomas, shows negligible activity in PCNSL, and its addition to HD-MTX did not improve outcome with respect to the use of HD-MTX alone. As a consequence, CHOP and CHOP-like regimens have been abandoned, and chemotherapy combinations for PCNSL are currently designed by using drugs with a moderate-to-high capacity to cross the BBB.
High-dose MTX
HD-MTX constitutes the backbone of most chemotherapy combinations used in PCNSL, with efficacy proven in prospective trials. Different regimens have been used in an attempt to improve efficacy (Table 2) ; MTX doses from 1 to 8 g/m 2 are feasible in PCNSL; both, total dose and infusion rate, are important for MTX delivery to the brain parenchyma and CSF. Patients treated with 43 g/m 2 reliably achieve sufficient CSF levels of MTX with a rapid (3 h) infusion. 82, 83 Although CSF levels are easily measured, they may not accurately reflect drug availability in areas of bulky tumor that are contrast-enhancing. This may even explain how doses as low as 1 g/m 2 MTX can still prolong survival even though CSF levels are likely subtherapeutic. Three different doses have been used in clinical trials assessing MTX single-agent activity in PCNSL (Table 2) : MTX dosed at 1 g/m 2 before WBRT; 53 MTX 3.5 g/m 2 every 2-3 weeks followed by WBRT 62, 72 and MTX 8 g/m 2 every 2 weeks deferring WBRT until failure. 55, 64 In trials using MTX 1 g/m 2 before WBRT, the 3-year OS was 45-50%. 53 HD-MTX at 8 g/m 2 yielded an overall response rate of 51 and 68%, with a 3-year OS of 33 and 35%, 55, 64 which is similar to the 3-year OS of 32-47% recorded in trials evaluating 3.5 g/m 2 . 62, 72 Noteworthy, dose reduction owing to impaired creatinine clearance was needed in 45% of patients in trials using MTX 8 g/m 2 , whereas in the 3.5-g/m 2 trials few patients needed reduction in MTX dose. Thus, the tolerability and activity of 3.5 g/m 2 suggest this may be a good compromise between safety and efficacy, particularly when the drug is used in combination regimens. In an attempt to overcome the limited BBB permeability of MTX, a total of 149 patients have been treated for in four centers with intra-arterial infusion of MTX-based chemotherapy after osmotic BBB disruption between 1982 and 2005, of whom long-term follow-up has been published: Of those, 131 (88%) had been treated within formal single-arm prospective trials; overall response in the 149 patients was 81.9%, median OS 3.1 years and median PFS 1.8 years. WBRT had not been applied and a subset of patients undergoing formal neuropsychometric testing 1-7 years after the procedure showed improvement or preservation of cognitive function. While obviously long-term neurotoxicity could be avoided by this approach, one has to note that this procedure is technically demanding, needs general anesthesia and had been accompanied by significant acute complications such as generalized seizures in 33.6% of patients, carotid or vertebral injury in 10.7%, and clinical stroke in 7.4%. 84 
Table 2
Published prospective trials on PCNSL in immunocompetent patients treated with chemotherapy alone or combined treatment No., number of enrolled patients; NS, not specified; NR, not reported. #, 5-year risk rate (updated from The Lancet 2009;374: 1512-1520) a Primary chemotherapy: A or H, adriamycin; a, cytarabine; B, bleomycin; Bn, BCNU; C, cyclophosphamide; Cn, CCNU; E, etoposide; M, methotrexate; m, nitrogen mustard; N, procarbazine; O, vincristine; P, prednisone or other corticoids; R, rituximab; T, thiotepa; V, teniposide; I, ifosfamid. Series using intra-thecal chemotherapy (It CHT) exclusively in patients with positive CSF cytology at diagnosis are indicated by asterisk. Treatment sequence: C, chemotherapy alone; CR, chemotherapy followed by radiotherapy; CRC, chemotherapy followed by radiotherapy and further chemotherapy. c ORR: Overall response rate; in series treated with combined modality, response rate after chemotherapy and (-) after the entire planned treatment are reported. d CRR: Complete remission rate; in series treated with combined modality, response rate after chemotherapy and (-) after the entire planned treatment are reported.
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High-dose cytarabine
Two studies suggested improvement when HD-Ara-C is added to MTX. 61, 72 In a recently published randomized trial, 72 79 patients with newly diagnosed PCNSL were assigned to four cycles of HD-MTX (3.5 g/m 2 ) either alone or combined with HD-Ara-C (2 g/m 2 ; days 2 þ 3); in both arms, the respective regimen was followed by WBRT. The addition of HD-Ara-C resulted in a significantly improved outcome, with CR rates of 18% and 46% (P ¼ 0.006) and a 3-year OS of 32% and 46% (P ¼ 0.07), respectively. Hematological toxicity was higher in the combination arm, whereas non-hematological toxicities were uncommon. The authors concluded to regard the HD-MTX/HD-Ara-C combination the current standard therapeutic approach for de novo PCNSL.
Rituximab
Rituximab is an anti-CD20 monoclonal antibody active in various B-cell lymphoma entities. The addition of this monoclonal antibody to CHOP has improved the survival of patients with DLBCL. As PCNSL is also predominantly a B-cell neoplasm, it is possible that rituximab could improve disease control in PCNSL. However, as a large protein it has poor penetration into the CNS as measured by CSF levels. 71 Addition of rituximab to CHOP was reported to prevent the CNS dissemination of DLBCL in a retrospective German analysis of 1222 patients over 60 years of age, which, however, was not confirmed in a French randomized trial including 399 patients. 78 The combination of rituximab and HD-MTX-based chemotherapy proved feasible in 30 PCNSL patients, with CR rates of 78% and a 2-year OS of 67%. 71 However, the precise role of rituximab in PCNSL remains to be defined.
Other drugs
Glucocorticoids and some alkylating agents with good CNS penetration, such as temozolomide, thiotepa, ifosfamide, nitrosoureas and procarbazine, have been included in chemotherapy combinations for PCNSL. Steroids generate tumor regression in a substantial fraction of PCNSL patients. 85 Consequently, as steroids induce apoptosis of the malignant B cells, they may preclude establishing the diagnosis and, thus, should be strictly avoided prior to biopsy. They should be used only in patients whose survival is imminently threatened by herniation. Tumor regression with steroids has also been proposed as a prognostic factor in PCNSL, but the real benefit of adding steroids to MTX-based chemotherapy remains undefined. Importantly, immunosuppression by prolonged steroid treatment should be avoided.
Temozolomide is an oral alkylating agent with a good safety profile and it can penetrate the BBB. This drug proved active in inducing CR in 25% of patients with relapsed or refractory PCNSL 86 and can be combined with HD-MTX in elderly patients. This is relevant as about 50% of PCNSL patients are older than 60 years, requiring drugs with a good safety profile and low hematological toxicity.
Ifosfamide, another alkylating agent, improved the CR of HD-MTX from 32 to 42% and reduced the primary progression rate from 26 to 15% in the G-PCNSL-SG1 trial, however, with a higher toxicity, particularly in elderly patients. 73 Thiotepa is a lipophilic alkylator that has been combined with HD-MTX, HD-Ara-C, idarubicin and WBRT. 60 This regimen resulted in an overall response rate of 83%, a median PFS of 13 months and a 5-year OS of 41% in a phase-II trial with a plateau in the survival curve, however, with a lethal toxicity of 10%.
Thiotepa was also included as part of induction and conditioning regimens in programs of high-dose chemotherapy (HDCT) supported by autologous stem cell transplantation (ASCT, see below). Procarbazine is a lipophilic, oral alkylating drug that has been largely used in a combination with HD-MTX and vincristine, followed by WBRT and HD-Ara-C, with a 5-year OS of 32%. 59 Carmustine or BCNU has been used in patients with PCNSL both as part of primary chemotherapy or in conditioning regimens before ASCT. Together with temozolomide, topotecan, a topoisomerase-II inhibitor with good CNS bioavailability, is the only drug that was prospectively studied as a single agent in relapsed/refractory PCNSL, resulting in a 19% CR and a 1-year OS of 39%. 87 Thus, temozolomide and topotecan are clear candidates for further development in PCNSL.
Intra-ventricular therapy
There is currently no consensus on CSF prophylaxis in PCNSL. The rate of leptomeningeal involvement in PCNSL is difficult to determine: Estimates vary according to diagnostic strategies used, ranging from 8% as determined by MRI 2 to 17% assessed by CSF analysis combining cytology and PCR-based methods. 4 Because systemically administered HD-MTX (1-8 g/m 2 ) achieves therapeutic concentrations in the CSF, one may question the impact of additional local therapy within this compartment. Thus, a multicenter trial assessed whether targeting the CSF as part of an intensified chemotherapy-only regimen would lead to durable responses. 68 Patients with newly diagnosed PCNSL (n ¼ 65) were treated with HD-MTX (5 g/m 2 ), HD-Ara-C (3 g/m 2 ), vincristine, alkylating agents and dexamethasone. This was combined with daily intraventricular chemotherapy consisting of MTX, steroids and Ara-C. Median event-free survival was 21 months and OS was 50 months at a median follow-up of 26 months. The response rate in this trial was 71% (61% CR, 10% partial remission (PR)); 19% of patients progressed during therapy and treatment-related mortality was 8%. Better outcome was observed in patients o60 years with Kaplan-Meier estimates for OS, PFS and event-free survival not yet reached. A recent follow-up showed that 57% of patients o60 years were alive after a median follow-up of 100 months. 88 This analysis also documented the absence of chemotherapyrelated neurotoxicity in 19 of 21 long-term survivors. However, Ommaya reservoir infections occurred in 19% of the patients in this trial. Thus, intraventricular treatment was omitted in a subsequent cohort of patients. Eighteen patients o60 years were treated with identical chemotherapy without intra-ventricular treatment. 89 At a median follow-up of 23 months, response rates were comparable to those obtained in the original trial; however, omitting intraventricular therapy resulted in a significantly shorter median PFS as compared with the original protocol. More than half of the responders suffered from relapse within the first year, 89 prompting premature termination of this trial. Assessment of Karnofsky performance status, lactate dehydrogenase levels and CSF protein at diagnosis indicated that study populations were very similar to the original study population with regard to these prognostic factors. 8, 9 As no other component of the protocol had been changed, these results suggest a benefit from the inclusion of intra-CSF therapy in the initial treatment of PCNSL, and support the assumption that targeting the CSF is necessary to achieve sustained remission. These data may also support the hypothesis that the CSF acts as a reservoir for surviving tumor cells, resulting in relapse.
Two retrospective analyses do not suggest a beneficial role of intraventricular treatment. 61, 90 In the case control series of Khan et al., 90 intraventricular MTX was administered twice weekly alternating with systemic HD-MTX. There was no benefit to the addition of intra-thecal chemotherapy. Therefore, the role of intrathecal chemotherapy remains undefined in PCNSL.
HDCT and stem cell transplantation
Based on the experience in other hematological malignancies and the need for effective consolidation treatment, HDCT followed by ASCT was also evaluated in PCNSL. The first experience with HDCT and ASCT in PCNSL was published in 2001 by Soussain et al. 91 Twenty-two patients with recurrent or refractory PCNSL or intraocular lymphoma were treated with HDCT and ASCT either initially at the time of relapse or following induction chemotherapy. Induction chemotherapy consisted of thiotepa (250 mg/m 2 /day, days 29 through 27), busulfan (10 mg/kg, total dose days 26 through 24) and cyclophosphamide (60 mg/kg/day, days 23 and 22) . The CR rate after the whole treatment was 80%, and the 3-year OS and event-free survival was 63.7% and 53%, respectively. The first report on HDCT and ASCT as first-line treatment included 28 patients receiving induction with systemic MTX (3.5 g/m 2 ) and Ara-C (3 g/m 2 for 2 days); BEAM was selected as conditioning regimen before ASCT. 92 The response rate to the induction chemotherapy was 57%. Only 50% of the patients completed HDCT and ASCT, resulting in 8/14 CR and 2/14 PR. These results were disappointing as the investigators observed a high relapse rate and median event-free survival of 5.6 months. Two further trials with BEAM conditioning and consolidating WBRT 93 reported better long-term disease control, but a substantial proportion of patients developed neurotoxicity, in part because they included WBRT after completion of all chemotherapy. Other HDCT strategies were used as part of front-line treatment in PCNSL, with more encouraging results when thiotepa-based conditioning regimens were used: 93 In one phase-II study, 30 patients with PCNSL o65 years received sequential induction chemotherapy, including three cycles of HD-MTX (8 g/m 2 ), HD-Ara-C (2 Â 3 g/m 2 ) and thiotepa (40 mg/m 2 ) followed by stem cell harvest. The conditioning regimen consisted of carmustine (400 mg/m 2 ) and thiotepa (2 Â 5 mg/kg body weight) followed by ASCT; WBRT (45 Gy) was given as consolidation. Twenty-three of the 30 patients proceeded to HDCT, resulting in CR and PR in 15 and 8 patients, respectively. Twenty-one patients subsequently underwent WBRT and all achieved CR. With a median follow-up of 63 months, the 5-year OS was 69% for all patients and 87% for those completing HDCT and ASCT. The 5-year relapse-related mortality was 21% for all patients (n ¼ 30) and 8.7% for those 23 treated with HDCT and ASCT, respectively. In a follow-up pilot study, induction chemotherapy was intensified, the thiotepa dose was doubled and only those patients who did not achieve CR after induction therapy underwent WBRT. 94 Seven of 11 patients were in CR following ASCT and three in PR upon ASCT received radiotherapy as consolidative treatment. After a median followup of 25 months, 3-year OS was 77%. None of the patients suffered from severe neurotoxicity during the follow-up period. Both of these trials suggest a curative effect of HDCT in young PCNSL patients. This concept, supplemented by rituximab immunotherapy, is currently under investigation (ClinicalTrials. gov identifier: NCT00647049).
Whether the discrepancies in effectiveness between BEAM and thiotepa-based conditioning regimens are related to the different capacity of these drugs to cross the BBB or have to be attributed to the efficacy of the specific agents, is still a matter of debate.
The impact of HDCT in PCNSL also depends on successful induction chemotherapy leading to optimal cytoreduction prior to HDCT. However, the choice of drugs within the conditioning regimen may have an important role in determining the potential curative effect of this approach in the front-line therapy of PCNSL. To date, only small series and phase-II trials have demonstrated feasibility and high efficacy of HDCT in PCNSL. To further investigate the potential benefit of this approach in PCNSL, an international intergroup trial is currently enrolling patients on a randomized phase-II trial, with those responding randomized between WBRT and HDCT (ClinicalTrials.gov identifier: NCT01011920).
Treatment-related late neurotoxicity
Deleterious long-term treatment-related neurotoxicity after combination chemotherapy and radiotherapy has been reported in a single-center analysis in 1998. 53 After having survived 4 years without a detectable tumor, 100% of the patients being 60 years or older showed cognitive dysfunction. Younger individuals were affected less frequently and with a longer delay by this complication. The affected patients showed leukoencephalopathy and cortical/sub-cortical atrophy, which may leave them demented, ataxic, incontinent and dependent on custodial care. 53 In a more recent retrospective analysis of the same center on 183 patients for the development of long-term treatment-related toxicity, only administration of radiotherapy was identified as an independent risk factor. 95 This finding is supported by a review of the literature suggesting that PCNSL patients having been treated with chemotherapy alone carry less risk to develop late neurotoxicity, 96 and by the G-PCNSL-SG1 trial, in which patients developed clinically more apparent late neurotoxicity in the radiotherapy arm, 73 although neurotoxicity was also observed in the chemotherapy arm. However, most reports do not include long-term follow-up of patients to assess the true risk of neurotoxicity associated with a regimen. Therefore, formal neuropsychological testing in any prospective therapeutic trial in PCNSL is recommended and guidelines for testing have been established. 96 
Conclusion
Despite its increasing incidence, PCNSL still is a rare disease. This requires an intense cooperation among the various fields. It is a prerequisite to treat patients in large, multi-center trials by experts in stereotactic neurosurgery, neurology, hematooncology and radiooncology. Simultaneously, patients' tumor tissues need to be evaluated by expert neuropathologists and pathologists to ensure diagnosis and consider relevant differential diagnoses. Importantly, an accompanying research program needs to address questions of PCNSL biology in the setting of clinical trials as a valid basis for correlation of clinical and molecular data in order to reveal biomarkers, which may help stratify patients to specific therapeutic regimens, and which may have a prognostic impact on the course and the outcome of this disease.
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